Skip to the page

Data / Medical devices / United States / Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics, Inc.: FDA-registered device maker in Malvern, PA, United States, 2 510(k) clearances

Fujirebio Diagnostics, Inc. is registered with the FDA (registration 2521625) in Malvern, PA, United States. It lists 20 device types. The FDA files 2 510(k) clearances under its listings, the newest dated May 16, 2025. 2 recall events name it as the recalling firm. Registered through 2026. FDA data exported November 2, 2026.

SpecStream is the live web data engine for teams and agents. It reads the FDA registration and listing, 510(k), PMA, recall and enforcement files from openFDA every week, and this page is that reading, joined by the FDA's own numbers. Ask for the makers of any device type in any country and new clearances, approvals and recalls arrive in your sheet, CRM, Slack or agent as the FDA publishes them.

FDA registration number
2521625
Address
201 Great Valley Parkway, Malvern, PA, United States, 19355
Owner or operator
Fujirebio Diagnostics, Inc. (10022860)
Roles
Contract manufacturer, Manufacturer, Manufacturer for export
First device listed
October 17, 2007
Registered through
2026
Brand names listed
ADVIA Centaur XPT Cytokeratin Fragment 21-1 MCM (CYFRA MCM) - Siemens, ADVIA Centaur XPT Tumor Marker Quality Controls (TMQC) - Siemens, ARCHITECT BNP Calibrators (China), ARCHITECT BNP Reagents (China), ARCHITECT BNP Reagents, Calibrators and Controls, ARCHITECT BNP-JP Calibrators, ARCHITECT BNP-JP Controls, ARCHITECT BNP-JP Reagents and more

Devices it lists

DeviceProduct codeClassRoleSource
Alzheimer’S Disease Pathology Assessment TestQSE2Manufactureraccessdata.fda.gov
Calibrator, SecondaryJIT2Contract manufactureraccessdata.fda.gov
Calibrators, Drug SpecificDLJ2Contract manufactureraccessdata.fda.gov
CyclosporineMKW2Contract manufactureraccessdata.fda.gov
Cytokeratin Fragments 21-1 Eia KitOVK2Manufacturer for exportaccessdata.fda.gov
Enzyme Immunoassay, MethotrexateLAOUManufacturer for exportaccessdata.fda.gov
Enzyme Immunoassay, TracrolimusMLM2Contract manufactureraccessdata.fda.gov
Galectin-3 In Vitro Diagnostic AssayOSX2Contract manufactureraccessdata.fda.gov
Immunoassay Blood Test For Amyloid Pathology AssessmentSET2Manufactureraccessdata.fda.gov
Ovarian Adnexal Mass Assessment Score Test SystemONX2Contract manufactureraccessdata.fda.gov
Prostate-Specific Antigen (Psa) For Management Of Prostate CancersLTJ2Contract manufactureraccessdata.fda.gov
Reagent, Coronavirus SerologicalQKONContract manufactureraccessdata.fda.gov
Single (Specified) Analyte Controls (Assayed And Unassayed)JJX1Contract manufacturer, Manufactureraccessdata.fda.gov
Sirolimus Test SystemNRP2Contract manufactureraccessdata.fda.gov
System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic CancerNIG2Contract manufactureraccessdata.fda.gov
System, Test, Immunological, Antigen, TumorMOI2Contract manufactureraccessdata.fda.gov
System, Test, ThyroglobulinMSW2Manufacturer for exportaccessdata.fda.gov
Test, Epithelial Ovarian Tumor Associated Antigen (He4)OIU2Contract manufactureraccessdata.fda.gov
Test, Epithelial Ovarian Tumor-Associated Antigen (Ca125)LTK2Contract manufactureraccessdata.fda.gov
Test, Natriuretic PeptideNBC2Contract manufactureraccessdata.fda.gov

510(k) clearances

The 510(k) numbers this establishment lists, with the FDA decision on each. The applicant is the company that holds the clearance.

Decided510(k) numberDeviceProduct codeDecisionApplicantSource
May 16, 2025K242706Lumipulse G pTau217/ß-Amyloid 1-42 Plasma RatioSETSubstantially EquivalentFujirebio Diagnostics,Inc.accessdata.fda.gov
May 4, 2022DEN200072Lumipulse G ß-Amyloid Ratio (1-42/1-40)QSEUnknownFujirebio Diagnostics,Inc.accessdata.fda.gov

Recalls

Recall events where this establishment is the recalling firm, matched on its FEI.

InitiatedEventClassStatusProductReasonSource
December 11, 202598232Class IIOngoingProduct Name: Lumipulse G pTau217/B-Amyloid 1-42 Plasma Ratio Model/Catalog Number: CL0073 Software Version: Not Applicable Product Description: Lumipulse G pTau217/-Amyloid 1-42 Plasma Ratio is an in vitro diagnostic (ICustomers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an incorrect classification of a patient as havaccessdata.fda.gov
July 29, 201056427Not yet classifiedTerminatedMESOMARK Humanitarian Device. Authorized by Federal Law for use as an aid in monitoring of patients diagnosed with mesothelioma. Each kit contains 96 tests. MESOMARK is an enzyme linked immunosorbent assay (ELISA) for thpresence of material attached to the bottom of some wells in places visible to the naked eye, which caused an overestimation of the sample.accessdata.fda.gov

Compare with other makers

Updated February 5, 2026. Read from openFDA bulk downloads (device registration and listing, 510(k), PMA, recall and enforcement files). CC0 1.0, public domain (openFDA terms of service). The files are joined on FDA identifiers: the 510(k) and PMA numbers a registration lists, and the recalling firm's FEI for recalls. Recall class comes from the FDA enforcement report. The FDA states that openFDA data is unvalidated and is not for decisions about medical care. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.